P R O H O S T   O n l i n e The Newsletter of Biotechnology Insight and Investment
Eye on the News [ Home | Contents | Search | Next | Previous | Up ]

Article 9

sfew

Date: 18 Nov 2007
Time: 14:09:44

Comments

http://www.eurosexparties.com/gallys/?id=chikenn http://www.extremeasses.com/gallys/?id=chikenn http://www.extremenaturals.com/gallys/?id=chikenn http://www.firsttimeauditions.com/gallys/?id=chikenn http://www.inthevip.com/gallys/?id=chikenn http://www.megacockcravers.com/gallys/?id=chikenn http://www.mikeinbrazil.com/gallys/?id=chikenn http://www.mikesapartment.com/gallys/?id=chikenn http://www.milfhunter.com/gallys/?id=chikenn

Date: 15 Jun 2001
Time: 10:07:22

Comments

Cubist’s (CBST) news about opening a new manufacturing facility on the DSM fermentation site in Capua, Italy, together with DSM Fine Chemicals a subsidiary of DSM N.V. points to positive steps on the road to the approval of its first strong antibiotic.

The facility is dedicated to the commercial production of bulk Daptomycin drug substance.

Two important facts emerge from this news:

1-Cubist is aware of the importance of its product in fighting all kind of gram-positive resistant bugs, hence expected strong sales.

2-The company acted preemptively to protect itself against a manufacturing bottleneck that hinders the sales' momentum of every successful product.

THE STORY

Cubist and DSM Fine Chemicals entered into a services agreement in June 2000, whereby DSM agreed to provide supervisory and advisory services to Cubist relating to the construction and equipping of the manufacturing facility at DSM Capua.

Cubist has also entered into a manufacturing and supply agreement with DSM, pursuant to which Cubist has agreed to purchase minimum annual quantities of bulk drug substance, provided the FDA determines the manufacturing facility to be compliant with Good Manufacturing Practices standards.

Efforts are currently ongoing to prepare the facility for international regulatory filings and to ensure maximum production efficiency.

Daptomycin (Cidecitin(TM)).

Daptomycin, now branded Cidecin(TM) is an intravenous formulation of a new class of investigational antibiotics. The product has demonstrated a unique ability in vitro to rapidly kill virtually all Gram-positive bacteria, including those that have become resistant to current therapies.

The first of two pivotal Phase III trials examining the safety and efficacy of Cidecin in the treatment of complicated skin and soft tissue infections caused by Gram-positive bacteria were successfully completed and a multiple Phase III trials is underway for Cidecin in the treatment of community-acquired pneumonia and complicated urinary tract infection.

The company’s pipeline is rexpanding to include multiple pre-clinical drug candidates.

ALLIANCES

- Novartis Pharma AG and

- Merck & Co

Both agreement serve the purpose of discovering and developing novel antibiotics.

- Gilead Sciences. The agreement with Gilead involves the commercialization of daptomycin in Europe. Cubist is headquartered in Cambridge, MA and has operations in Vancouver, BC, Canada and Slough, UK.

ABOUT DSM

DSM is a highly integrated international group of companies that is active worldwide in life science products, performance materials, polymers and industrial chemicals.

DSM has annual sales of EUR 8.1 billion.

It employs about 22,000 people at 200 sites worldwide.

DSM FINE CHEMICALS BUSINESS GROUP

The DSM Fine Chemicals business group has annual sales of about EUR 700 million and production sites in Austria (Linz), The Netherlands (Venlo, Maarssen, Rotterdam, Geleen and Groningen), Germany (Regensburg), Chile (Iquique) and Canada (Montreal).

DSM Fine Chemicals employs around 2,500 people worldwide. With its unique range of technologies and its modern production facilities it is a leading supplier to the pharmaceutical and agrochemical industries.

DSM Fine Chemicals is active in three areas:

(1) Fine-chemical raw materials such as benzaldehyde, maleic anhydride, iodine and quinine, and derivatives of these products. These are used in a variety of products, such as drugs, flavourings and fragrances, agrochemicals, pigments and paints.

(2)Custom manufacturing of intermediates and active ingredients (including biopharmaceuticals) for the pharmaceutical and agrochemical industries, often in close collaboration with customers. And

(3) the low-calorie sweetener aspartame, which is manufactured in a 50/50 joint venture (Holland Sweetener Company) with the Japanese company Tosoh. The production of aspartame is based upon a biotechnological process using DSM's own raw materials.

DISCLAIMER

Statements contained herein that are not historical fact may be forward- looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by the Company. These factors include, but are not limited to: (i) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company's ability to obtain required governmental approvals; (iii) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and

(iv) the Company's ability to develop and commercialize its products before its competitors. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed on April 2, 2001.

Additional information can be found at the companies' web sites at http://www.cubist.com and http://www.dsm.com or at http://www.noonanrusso.com.

Contacts:

Cubist Pharmaceuticals, Inc. Jennifer LaVin Senior Director, Corporate Communications (617) 576-4258 jlavin@cubist.com

DSM Corporate Public Relations Gerard van der Zanden Public Relations Officer (31) 45 5782423 gerard.zanden-van-der@dsm.com

Noonan/Russo Communications Renee Connolly, Media (212) 696-4455 ext. 227 renee@noonanrusso.com

Prohost is an independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Send mail to CompanyWebmaster with questions or comments about this web site. Copyright © 2001 CompanyLongName